Zambia Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2373634
  • January 2013
  • Region: Zambia
  • 41 pages
  • Business Monitor International
1 of 3

BMI View:

The majority of investment in Zambia's healthcare market stems from international aid agencies - so the news that the government has increased its allocation for healthcare spending in the 2013 budget will be well received by both NGOs and international investors as a sign that Zambia is taking its commitment to healthcare seriously. The country suffers from a burden of both communicable and non-communicable diseases, with a high incidence of HIV and AIDs, malaria, and problems such as cholera emerging in Q412, but it is making progress. The government claims it has already met its millennium development goals for turbercolosis, and is on target to meet other healthcare goals. Risks remain, such as the presence of counterfeit and substandard drugs, and the reliance on copper export means Zambia's economy has a narrow base.

Headline Expenditure Projections

- Pharmaceuticals: ZMK951bn (US$196mn) in 2011 to ZMK1,095bn (US$207mn) in 2012;
+15.1% in local currency terms and +5.7% in US dollar terms. Forecast lowered slightly from Q412.

- Healthcare: ZMK5,347bn (US$1.10bn) in 2011 to ZMK6,290bn (US$1.19bn) in 2012; +17.6
%in local currency terms READ MORE >

Note: Product cover images may vary from those shown
2 of 3

BMI Industry View 5

Pharmaceutical Risk/Reward Ratings 7
Table: MEA Pharmaceuticals And Healthcare Risk/Reward Ratings, Q113 7

Rewards 8

Risks 9

Market Summary 10

Government Healthcare Reform 12

Regulatory Regime 17

Pharmacovigilance (PV) 20

Industry Forecast Scenario 23

Pharmaceutical Market Forecast 23
Table: Pharmaceutical Sales Indicators 2008-2016 24

Healthcare Market Forecast 25
Table: Healthcare Expenditure Indicators, 2008-2016 27
Table: Healthcare Governmental Indicators, 2008-2016 28
Table: Healthcare Private Indicators, 2008-2016 28

Key Growth Factors - Macroeconomic 29

Demographic Outlook 31
Table: Zambia's Population By Age Group, 1990-2020 ('000) 32
Table: Zambia's Population By Age Group, 1990-2020 (% of total) 33
Table: Zambia's Key Population Ratios, 1990-2020 34
Table: Zambia's Rural And Urban Population, 1990-2020 34

Glossary 35

BMI Methodology 37

How We Generate Our Pharmaceutical Industry Forecasts 37

Risk/Reward Ratings Methodology 38

Ratings Overview 38
Table: Pharmaceutical Business Environment Indicators 39

Weighting 40
Table: Weighting Of Components 40

Sources 40

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.